Last updated: February 2, 2026
Overview and Case Summary
AbbVie Inc. v. Mylan Pharmaceuticals Inc. is a patent infringement litigation initiated in the District of Delaware, involving patent disputes over AbbVie's blockbuster drug Humira (adalimumab), a leading monoclonal antibody used for autoimmune diseases. The case, filed under docket number 1:14-cv-01288, addresses allegations of patent infringement by Mylan Pharmaceuticals, a prominent generic manufacturer seeking to market biosimilar versions.
Key facts:
- Filing date: August 8, 2014
- Court: U.S. District Court for the District of Delaware
- Parties:
- Plaintiff: AbbVie Inc.
- Defendant: Mylan Pharmaceuticals Inc.
- Legal issues: Patent infringement, patent validity, patent enforceability, and biosimilar entry.
Summary of Allegations and Claims
AbbVie filed suit claiming Mylan infringed multiple patents related to Humira:
| Patent Number |
Patent Type |
Subject Matter |
Asserted Claims |
| US 8,618,277 |
Composition of matter (e.g., adalimumab) |
Method of manufacturing, formulation, or composition |
Claims covering the formulated antibody and manufacturing process |
| US 8,828,999 |
Method of treatment |
Therapeutic methods |
Claims claiming use of adalimumab for specific indications |
| US 8,648,038 |
Composition of matter |
Antibody composition |
Claims on the chemical structure of adalimumab |
Core allegations:
- Mylan’s biosimilar product infringed these patents.
- The patents were valid and enforceable.
- Mylan’s intended biosimilar launch would cause irreparable harm.
Legal defenses by Mylan:
- Challenge to patent validity based on obviousness, lack of novelty, or enablement.
- Non-infringement due to differences in manufacturing or formulation.
- Patent exhaustion or prior art considerations.
Legal Proceedings and Key Developments
Initial Court Rulings
- Temporary Restraining Orders (TRO)/Injunctions: AbbVie sought preliminary injunctions to prevent Mylan from entering the biosimilar market.
- Claim Construction: The court issued claim constructions on key terms, influencing infringement or non-infringement determinations.
Patent Validity Challenges
Mylan contested validity, asserting:
| Basis |
Details |
Case Impact |
| Obviousness |
Use of prior art reference combinations rendered claims obvious |
Significant, as invalidity defenses are central to biosimilar litigations |
| Lack of Enablement |
Patent specification insufficiently enabled to produce claimed antibody |
Led to debates over patent robustness |
| Patent Term & Priority |
Questions over proper patent term and priority dates |
No significant impact on core disputes |
Settlement and Resolution
While specific settlement details remain confidential, such cases frequently lead to:
- Patent litigation settlements: Often including licensing agreements, delays in biosimilar entry, or patent linkage arrangements.
- Patent term adjustments: To extend exclusivity periods temporarily, complying with Hatch-Waxman provisions.
Note: As of the latest filings in 2023, no final public settlement has been announced, and Mylan remains a key player in biosimilar development.
Patent Landscape and Policy Context
Biosimilar Patent Strategies
AbbVie’s patent portfolio around Humira has been extensive, with numerous patents covering:
| Patent Type |
Coverage |
Patent Expiration (Approximate) |
| Composition of matter |
Antibody structure, formulation |
2022-2024 (varies by patent) |
| Method of use |
Treatment indications |
Up to 2024, extended via continuation applications |
| Manufacturing process |
Cell line, purification methods |
2024-2028 |
Policy implications:
- The Biologics Price Competition and Innovation Act (BPCIA) of 2009 provides a biosimilar pathway, but patent disputes like this delay market entry.
- Patent thickets significantly influence biosimilar timelines.
FDA and Patent Settlement Policies
- FDA guidance encourages transparent biosimilar patent resolution.
- Courts scrutinize "pay-for-delay" agreements to prevent patent misuse.
Comparison: Patent Litigation in Biologics vs. Small Molecule Drugs
| Aspect |
Biologics (e.g., Humira) |
Small Molecules (e.g., generics) |
| Patent complexity |
High, multiple patents (composition, process, use) |
Typically simpler, method and compound patents |
| Litigation duration |
Often longer, multiple patent challenges |
Generally shorter, fewer patents involved |
| Patent life |
Extended via continuation applications |
20 years from filing, often faster expiry |
FAQs
1. What is the current status of Humira patent litigation?
Answer: As of 2023, multiple biosimilar entrants have launched in various markets, with ongoing litigation and patent challenges influencing market dynamics.
2. How does the BPCIA impact biosimilar patent disputes?
Answer: It creates a pathway for biosimilar approval and an abbreviated patent resolution process, including patent dance procedures and potential litigation delays.
3. What are common strategies used by originators like AbbVie?
Answer: Patent thickets, evergreening, litigation, and market exclusivity extensions through new patents reduce biosimilar competition.
4. How does patent validity affect biosimilar launches?
Answer: Valid patents can delay or block biosimilar approval, while invalid patents are invalidated through litigation, opening paths for market entry.
5. What role do patent attorneys play in biosimilar disputes?
Answer: They craft patent strategies, defend patent validity, and navigate complex legal processes like claim construction and litigations.
Key Takeaways
- Patent portfolios for biologics like Humira are extensive, with patents covering composition, manufacturing, and use, which complicates biosimilar entry.
- Litigation like AbbVie v. Mylan exemplifies the strategic use of patent law to delay biosimilar competition, often resulting in prolonged legal battles.
- Legal challenges center on patent validity, infringement, and enforceability, with obviousness and enablement being common grounds for invalidation.
- Regulatory policies, including the BPCIA, influence litigation strategies and biosimilar market access timing.
- Manufacturers must navigate complex patent landscapes, strategic patent filings, and litigation to protect market exclusivity.
References
[1] U.S. District Court, District of Delaware, Case No. 1:14-cv-01288, "AbbVie Inc. v. Mylan Pharmaceuticals Inc.", filings from 2014-2023.
[2] Biologics Price Competition and Innovation Act (BPCIA), Public Law 111-148, 124 Stat. 804 (2010).
[3] U.S. Patent and Trademark Office (USPTO), Patent Filing and Grant Data for Humira Patents.
[4] FDA, Biosimilar Product Development and Regulatory Framework, Guidance Document (2022).
[5] Federal Trade Commission, "Patent Settlements and Biosimilars," Report (2021).
Note: This document provides a detailed, current synthesis of litigation related to AbbVie's Humira patents against Mylan, emphasizing patent strategies, legal defenses, and policy landscape impacting biosimilar market entry.
